Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
ASND
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q2.23
N/A
-2.35
vs -1.54
Q3.23
N/A
-3.12
vs -3.05
Q4.23
N/A
-1.66
vs -3.78
Q1.24
N/A
-2.48
vs -2.12
Q2.24
N/A
-2.05
vs -2.35
Q3.24
N/A
-1.89
vs -3.12
Q4.24
N/A
-0.68
vs -1.66
Q1.25
N/A
-1.66
vs -2.48
Q2.25
N/A
-1.45
vs -2.05
Q3.25
N/A
-0.83
vs -1.89
Sales Growth
YoY
Current
Estimates
Q2.23
+669%
47.4M vs 6.2M
Q3.23
+214%
48M vs 15.3M
Q4.23
+501%
137.7M vs 22.9M
Q1.24
+185%
95.9M vs 33.6M
Q2.24
-24%
36M vs 47.4M
Q3.24
+20%
57.8M vs 48M
Q4.24
+26%
173.9M vs 137.7M
Q1.25
+5%
101M vs 95.9M
Q2.25
+305%
145.8M vs 36M
Q3.25
+244%
198.8M vs 57.8M
Return on Equity
QoQ
Q2.23
-187%
-1.87
vs -0.66
Q3.23
+221%
2.21
vs -1.87
Q4.23
+60%
0.6
vs 2.21
Q1.24
+55%
0.55
vs 0.6
Q2.24
+34%
0.34
vs 0.55
Q3.24
+102%
1.02
vs 0.34
Q4.24
+36%
0.36
vs 1.02
Q1.25
+50%
0.5
vs 0.36
Institutionnal Ownership
QoQ
Q2.23
175
175
vs 179
-2%
Q3.23
174
174
vs 175
-1%
Q4.23
202
202
vs 174
16%
Q1.24
206
206
vs 202
2%
Q2.24
215
215
vs 206
4%
Q3.24
235
235
vs 215
9%
Q4.24
224
224
vs 235
-5%
Q1.25
255
255
vs 224
14%
accessnewswire.com
6 hours ago
accessnewswire.com
6 hours ago
globenewswire.com
8 hours ago
Forecast
1160%2026-Revenue
230%2026-EPS
-2403%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
0.00(-100.00%)
Number of analyst
0
Last analyst upgrade/downgrade
Morgan Stanley
upgradePrevious: Equal-Weight
2025-05-05
Now: Overweight
RBC Capital
initialisePrevious: Not converted
2025-04-15
Now: Outperform
Cowen & Co.
upgradePrevious: Buy
2024-06-25
Now: Positive
Cowen & Co.
upgradePrevious: Not converted
2024-06-25
Now: Buy
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
NASDAQ
Unprofitable
Unprofitable
-0.63Â ( -0.36%)
Relative Strenght
84
Volume Buzz
-79%
Earning Acce
No
Dist 52w H.
6%Quote Panel
Key Metrics
Relative Strength
ASND
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
